Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 353-358

  Nakanishi, Masanori ^a   Yoshida, Yoshimasa ^a   Natazuka, Toshiki ^a  

^a Shinseikai Toyama Hospital   (Japan)

Author keywords

Angiography; Chemotherapy; Comorbidities; Elderly; Lung cancer; Performance status

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DISTANT METASTASIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THORAX PAIN; THROMBOCYTOPENIA; TOXICITY; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84863783951     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.006     Document Type: Article

References (34)

1. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
2. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
3. Robinson L.A., Ruckdeschel J.C., Wagner H., Stevens C.W. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:243S-265S.
4. Jett J.R., Schild S.E., Keith R.L., Kesler K.A. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:266S-276S.
5. Weir H.K., Thun M.J., Hankey B.F., Ries L.A.G., Howe H.L., Wingo P.A., et al. Annual report to the Nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95:1276-1299.
6. Gridelli C., Perrone F., Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997, 33:2313-2314.
7. Gridelli C., Maione P., Rossi A., Guerriero C., Ferrara C., Gaizo F.D., et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006, 17(Suppl. 5):v72-v78.
8. Buccheri G., Ferrigno D., Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996, 32A:1135-1141.
9. Radzikowska E., Glaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20651 cases. Ann Oncol 2002, 13:1087-1093.
10. Gridelli C., Ardizzoni A., Chevalier T.L., Manegold C., Perrone F., Thatcher N., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European Experts Panel. Ann Oncol 2004, 15:419-426.
11. Kemeny M.M., Adak S., Gray B., Macdonald J.S., Smith T., Lipsitz S., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002, 20:1499-1505.
12. Ganeshan A., Upponi S., Hon L.Q., Warakaulle D., Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008, 19:847-851.
13. Yiengpruksawa A., Watanabe G., Ono Y., Tsurumaru M., Akiyama H. Tracheoesophageal fistula as a result of bronchial artery infusion therapy. Int Surg 1984, 69:351-355.
14. Fujiyoshi F., Inoue H., Ikeda K., Hori A., Sakake M., Eiro I., et al. Complication of arterial infusion of CDDP for treatment of malignant neoplasms. J Japan Radiol Soc 1992, 52:928-933.
15. Cauldwell E.W., Siekert R.G., Lininger R.E. The bronchial arteries: an anatomic study of 150 human cadavers. Surg Gynecol Obstet 1948, 86:359-412.
16. Hellekant C., Johnsson K. Double blood supply of bronchial carcinoma from multiple arteries. Acta Radiol Diagnosis 1981, 22:403-406.
17. Nakanishi M., Umeda Y., Demura Y., Ameshima S., Chiba Y., Miyamori I., et al. Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases. Lung Cancer 2007, 55:241-247.
18. Nakanishi M., Demura Y., Umeda Y., Mizuno S., Ameshima S., Chiba Y., et al. Multi-arterial infusion chemotherapy for non-small cell lung carcinoma-significance of detecting feeding arteries and tumor staining. Lung Cancer 2008, 61:227-234.
19. Saadoon K. Regional anatomy of the thoracic aorta. Atlas of normal and variant angiographic anatomy 1991, W.B. Saunders Company.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
21. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
23. Moteki T., Ohya N., Katsuya T. Bronchial arterial angio-CT: evaluation of intradural and oesophageal enhancement before bronchial arterial infusion. Br J Radiol 1998, 71:834-839.
24. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer?. Lung Cancer 2002, 38:S45-S50.
25. Sweeney C.J., Zhu J., Sandler A.B., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001, 92:2639-2647.
26. Ramalingam S.S., Dahlberg S.E., Langer C.J., Gray R., Belani C.P., Brahmer J.R., et al. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 2009, 26:60-65.
27. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592: a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
28. Langer C., Li S., Schiller J., Tester W., Rapoport B.L., Johnson D.H. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007, 25:418-423.
29. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2191-2197.
30. Ohyanagi F., Yamamoto N., Horiike A., Harada H., Kozuka T., Murakami H., et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. British Journal of Cancer 2009, 101:225-231.
31. Naito Y., Kubota K., Nihei K., Fujii T., Yoh K., Niho S., et al. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol 2008, 3:617-622.
32. Vogl T.J., Lehnert T., Zangos S., Eichler K., Hammerstingl R., Korkusuz H., et al. Transpulmonary chemoembolization (TPSE) as a treatment for unresectable lung metastases. Eur Radiol 2008, 18:2449-2455.
33. Grootenboers M.J., Schramel F.M., van Boven W.J., Hendriks J.M., van Schil P.E., De Wit P.E., et al. Selective pulmonary artery perfusion followed by blood flow-occlusion: new challenge for the treatment of pulmonary malignancies. Lung Cancer 2009, 63:400-404.
34. Den Hengst W.A., Van Putte B.P., Hendriks J.M., Stockman B., van Boven W.J., Weyler J., et al. Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. Eur J Cardiothorac Surg 2010, 38:621-627.